The breadth of melatonin’s reported activities is striking. Beyond its sedative effect, the review catalogs antitumor, immunomodulatory, antioxidant, antihypertensive and cardioprotective actions, along with roles in regulating body weight, gastrointestinal function, reproduction and thermoregulation. Part of this versatility is chemical: melatonin crosses biological membranes freely and reaches nearly every compartment of the cell. Part of it is signaling: melatonin binds specific G-protein-coupled receptors, but it also engages intracellular pathways that govern whether a cell survives stress, divides, inflames or dies. The question the review tackles is which of these pathways best explains the hormone’s pharmacological reach, and its answer centers on SIRT1, the most intensively studied member of the mammalian sirtuin family.

SIRT1 is a nicotinamide adenine dinucleotide, or NAD+, dependent deacetylase, meaning it removes acetyl chemical groups from proteins only when the metabolic cofactor NAD+ is available. This makes the enzyme a direct sensor of cellular energy status, because NAD+ levels rise and fall with nutrient availability, fasting and metabolic strain. SIRT1 shuttles between the cytoplasm and the nucleus, where it strips acetyl groups from histones, the spools around which DNA is wound, and from a growing list of non-histone proteins including the tumor suppressor p53, the transcription factors FoxO and NF-κB, and the mitochondrial regulator PGC-1α. Through these targets, SIRT1 influences cell survival, metabolism, growth, aging and resistance to stress, which is precisely the portfolio of processes that goes wrong in chronic disease.

The review’s central claim is that melatonin can modulate SIRT1 activity, and that this modulation in turn shapes four fundamental cellular responses: inflammation, oxidative stress, apoptosis and autophagy. In inflammatory bowel disease, for example, recent work cited in the review shows that melatonin restores the intestinal mucosal barrier by activating a SIRT1-LKB1-pAMPK signaling axis. In autoimmune and sepsis models, SIRT1 deacetylates components of the NF-κB pathway and the NLRP3 inflammasome, damping the production of tumor necrosis factor alpha, interleukin-1 and other inflammatory mediators. Because NF-κB sits upstream of cyclooxygenase-2 and inducible nitric oxide synthase, a single deacetylation event can cascade into a broad suppression of the inflammatory program.

The cardiovascular evidence is among the most developed. In type 2 diabetic rats, reduced SIRT1 signaling worsens myocardial ischemia-reperfusion injury, and melatonin treatment restores protection through the enzyme. Melatonin receptor-mediated cardioprotection against ischemia-reperfusion has likewise been traced to SIRT1. In diabetic hearts, melatonin prevents Drp1-mediated mitochondrial fission, the excessive fragmentation of mitochondria that starves cardiomyocytes of energy, via the SIRT1-PGC-1α pathway, and activation of the SIRT1-PGC-1α-SIRT3 cascade protects against mitochondrial dysfunction in isoproterenol-induced myocardial injury. The chemotherapy drug doxorubicin, notorious for causing heart damage, appears less toxic when melatonin activates the Sirt1/Nrf2 pathway, inhibiting oxidative stress, pyroptosis and apoptosis. In sepsis-induced cardiac dysfunction, melatonin acts through SIRT1 to regulate both apoptosis and autophagy, including SIRT1-mediated deacetylation of beclin-1 and of the transcription factor TFEB, which orchestrates lysosomal clearance of damaged material.

The kidney tells a parallel story. Melatonin attenuates acute kidney ischemia-reperfusion injury in diabetic rats by activating the SIRT1/Nrf2/HO-1 axis, a canonical antioxidant pathway in which Nrf2, once deacetylated and stabilized, switches on heme oxygenase-1 and other detoxifying genes. In diabetic kidney disease, protection runs through SIRT1/NLRP3 signaling, curbing the inflammasome-driven inflammation that scars the filtering units of the kidney. Melatonin also prevents acute kidney injury in severely burned rats via SIRT1 activation, and in cadmium-induced proximal tubular injury it preserves mitochondrial function by blocking fission through SIRT1-PGC-1α. Perhaps most intriguingly, melatonin lowers the abundance of hypoxia-inducible factor 1α in human proximal tubular cells by preventing its deacetylation by sirtuin 1, a reminder that SIRT1’s effects are not uniformly protective but context-dependent, and that melatonin’s modulation of the enzyme can push it in either direction depending on the tissue and insult.

In the liver, the review highlights melatonin’s effects on non-alcoholic fatty liver disease, a condition now affecting a substantial share of the world’s overweight and obese population. Melatonin’s benefits in fatty liver models are linked to the microRNA-34a-5p/Sirt1 axis and to autophagy, the cellular recycling system that clears lipid droplets and damaged organelles. In hypercholesterolemic mice, melatonin’s modulation of sirtuin-1 attenuates liver injury. The enzyme also mediates protection against toxic exposures: melatonin inhibits benzo(a)pyrene-induced apoptosis in mouse liver through the miR-34a/Sirt1/autophagy pathway, and it attenuates arsenic-induced liver injury through Nrf2/HO-1, apoptosis and miR-34a/Sirt1/autophagy routes. In alcoholic liver injury, melatonin-induced SIRT1 disrupts the cereblon-YY1-CYP2E1 signaling pathway, reducing the oxidative metabolism of alcohol that generates damaging free radicals, while in sepsis-induced liver injury melatonin activates SIRT1/STAT3 signaling to rescue dysregulated gluconeogenesis.

The reproductive findings may prove the most clinically provocative. In polycystic ovary syndrome, melatonin enhances SIRT1 expression in granulosa cells to ameliorate excessive PINK1/Parkin-mediated mitophagy and to protect mitochondrial membranes through PDK1/Akt signaling, and it attenuates Drp1-driven mitochondrial fission through SIRT1 upregulation. The ROS/SIRT1/STAR axis has been identified as a target through which melatonin corrects atrazine-induced mitochondrial dysfunction and steroid disorders in granulosa cells. In oocytes, melatonin protects against chronic stress-induced meiotic defects by regulating SIRT1, and follicular fluid insufficiency of melatonin has been proposed as a reversible cause of the chromosomal abnormalities seen in oocytes of advanced maternal age. On the male side, melatonin protects mouse testes from palmitic acid-induced lipotoxicity in a SIRT1-dependent manner, ameliorates diabetic impairment of Leydig cell steroidogenic function through SIRT1 activation, and modulates SIRT1 to counter LPS-induced testicular nitro-oxidative stress and inflammation. Human trials add a translational note: melatonin supplementation improved semen parameters in men with idiopathic infertility in a triple-blind randomized placebo-controlled trial, and melatonin therapy added benefit to varicocelectomy in a double-blind trial, with epigenetic effects in a varicocele rat model mediated by silent information regulator 1.

The musculoskeletal section rounds out the picture. In osteoarthritis, melatonin exerts cytoprotective and anti-inflammatory effects in human chondrocyte cells and in rabbit models via the SIRT1 pathway, prevents cartilage matrix degradation by inhibiting NF-κB through SIRT1, and regulates chondrocyte hypertrophy and apoptosis through the Sirt1/P53/P21 axis. It also promotes sirtuin 1 expression to inhibit the IRE1α-XBP1S-CHOP branch of the unfolded protein response, reducing endoplasmic reticulum stress-mediated apoptosis in chondrocytes. In intervertebral disc degeneration, melatonin protects vertebral endplate chondrocytes against apoptosis and calcification via the Sirt1-autophagy pathway and holds promise through inhibiting M1-type macrophage polarization via SIRT1/Notch signaling. Even in cancer the relationship is bidirectional: whereas SIRT1 activation generally protects healthy tissue, melatonin’s antitumor activity in human osteosarcoma cells has been attributed to SIRT1 inhibition, underscoring that the same enzyme can be friend or foe depending on cellular context.

The authors are careful to note the limits of the evidence. Despite the breadth of preclinical data, they write that evidence regarding the role of SIRT1 in melatonin’s effects remains limited, and much of what is known comes from cell cultures and animal models rather than definitive human trials. Whether melatonin reliably activates SIRT1 in human tissues at supplement doses, and whether SIRT1 is necessary rather than merely correlated with the hormone’s benefits, will require pharmacological inhibitors, genetic models and properly powered clinical studies. Still, the synthesis is compelling in its coherence: a hormone produced by a tiny gland in the brain, acting through an NAD+-dependent enzyme that links metabolism to gene expression, appears to coordinate protective programs across organs as different as the heart, kidney, liver, ovary and joint. If future work confirms SIRT1 as the common mediator, melatonin’s humble reputation as a sleep aid may give way to something far more interesting, a cheap and safely tolerated molecule that tunes the body’s central longevity machinery.

Subject of Research: The role of the SIRT1 signaling pathway in the therapeutic effects of melatonin across disease models

Article Title: The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway

Article References: Vahidinia, Z., Behdarvandy, M., Azami Tameh, A., Barati, S., & Yasamian, A. (2026). The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway. Molecular Biology Reports, 53(1), Article 1667. https://doi.org/10.1007/s11033-026-12815-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12815-6

Keywords: melatonin, SIRT1, sirtuins, NAD+, deacetylation, oxidative stress, autophagy, apoptosis, cardioprotection, diabetic cardiomyopathy, non-alcoholic fatty liver disease, polycystic ovary syndrome

The study, published in Food Science of Animal Resources, used a whey-derived milk polar lipid concentrate containing at least 25 percent total phospholipids, including sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. Male C57BL/6J mice, a standard strain in metabolic research, were divided into four groups of six animals each. One group received a standard control diet, a second received a high-fat high-sucrose diet deriving 43 percent of its calories from fat and 24 percent from sucrose, a third received that same obesogenic diet modified so that milk fat was replaced with 8 percent of the milk polar lipid concentrate, and a fourth received the obesogenic diet supplemented with 0.01 percent orlistat, the pancreatic lipase inhibitor sold commercially as Xenical, serving as a positive control. The animals were followed for twelve weeks, with body weight and food intake recorded weekly and body composition assessed by dual-energy X-ray absorptiometry shortly before the study’s end.

The results were striking. Mice on the high-fat high-sucrose diet gained substantially more weight than controls, but the animals receiving milk polar lipids ended the study at a final body weight statistically indistinguishable from the normal-diet group. Fat mass, measured by DEXA scanning, was significantly lower in the supplemented animals, and the treatment partially restored lean mass while also improving bone mineral content, an intriguing secondary observation that suggests the lipids may help preserve skeletal status under metabolic stress. Food and calorie intake rose gradually in the unsupplemented high-fat group, but the researchers attributed this to increasing body mass rather than heightened appetite, noting that intake did not differ across groups during the early weeks when body weights were still comparable.

Blood chemistry told a similar story of protection. The obesogenic diet drove up total cholesterol and low-density lipoprotein cholesterol, both well-established indicators of dysregulated lipid metabolism, and elevated alanine aminotransferase and aspartate aminotransferase, the two enzymes clinicians rely on most heavily to detect liver cell damage. Supplementation with the milk lipid concentrate pushed all of these markers back toward normal levels. Serum triglycerides, curiously, were actually higher in the supplemented group than in the unsupplemented high-fat group, but the authors interpret this not as a metabolic failure but as a sign of enhanced lipid mobilization and export from liver and fat stores into circulation, consistent with prior evidence that dietary phospholipids influence very-low-density lipoprotein assembly and hepatic lipid handling. They caution that the relatively short four-hour fast before tissue collection may have introduced postprandial effects and call for future studies measuring free fatty acids and hepatic VLDL secretion rates to clarify the point.

Under the microscope, the differences were unmistakable. Adipocytes in the high-fat group were markedly enlarged, a hallmark of adipose tissue dysfunction that fuels chronic low-grade inflammation and floods peripheral organs with excess free fatty acids. Both the milk lipid and orlistat groups showed significantly smaller adipocytes and reduced weights of inguinal and mesenteric white adipose tissue depots. In the liver itself, hematoxylin and eosin staining and Oil Red O staining revealed heavy fat infiltration in the high-fat group, while the supplemented animals showed dramatically reduced steatosis, lower liver weights, and significantly reduced hepatic triglyceride content. Earlier work had suggested that milk phospholipids partly work by interfering with micellar lipid solubilization in the intestine, reducing absorption and increasing fecal lipid excretion, but the tiny amounts of intact phospholipids recovered in feces in prior studies indicated the supplements themselves are efficiently absorbed, hinting that they must also act systemically after uptake.

That systemic action is where the new study makes its most technically interesting contribution. The researchers probed the hepatic Wnt/β-catenin pathway, an evolutionarily ancient signaling cascade best known for orchestrating embryonic development but increasingly recognized as a metabolic regulator. The obesogenic diet significantly suppressed key components of the pathway, reducing hepatic expression of the co-receptor LRP6 and the ligand Wnt3a. Supplementation with the milk lipids, and to a comparable degree orlistat, restored LRP6 and Wnt3a expression, but only the milk lipid diet significantly upregulated total β-catenin, the pathway’s central transcriptional effector. When Wnt signaling is active, stabilized β-catenin enters the nucleus and suppresses adipogenic transcriptional programs driven by PPARγ and C/EBPα, thereby limiting lipid storage. Consistent with that model, the supplemented animals showed significantly reduced expression of PPARγ and its downstream partners DGAT1 and PLIN2, which govern triglyceride synthesis and lipid droplet formation, along with reduced SREBP1 and the de novo lipogenesis enzymes ACC, SCD1, and FAS.

The authors propose a plausible biophysical explanation for how dietary lipids could touch this membrane-anchored pathway. Polar lipids can alter the composition of cellular membranes, and membrane phosphoinositide metabolism is known to be essential for LRP6 activation, with prior work showing that Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Milk fat globule membrane supplementation has also been shown in lipidomic studies to enrich membranes in phosphatidylcholine and phosphatidylethanolamine. In other words, the phospholipids consumed in the diet may be incorporated into hepatic membranes in ways that sensitize the Wnt machinery, though the authors are careful to frame this as a plausible mechanism rather than a demonstrated one. Notably, milk-derived sphingomyelin has previously outperformed egg-derived sphingomyelin against hepatic steatosis, suggesting that the source and molecular composition of dietary lipids matter in ways the field is only beginning to map.

The second arm of the mechanism involves the gut microbiome, and here the study employed 16S rRNA gene sequencing of cecal contents processed through the DADA2 and QIIME pipelines. The obesogenic diet significantly reduced microbial alpha diversity, as measured by the Shannon index and phylogenetic diversity, and shifted the community structure into a cluster clearly separated from controls. The milk lipid group formed its own distinct cluster, separate from both the high-fat and orlistat groups, with PERMANOVA confirming significant separation between the supplemented and unsupplemented high-fat animals. Because the orlistat group’s microbiome remained similar to the high-fat group’s, the authors infer that the lipids’ microbial effects extend beyond simple inhibition of fat absorption. At the phylum level, supplementation partially reversed the diet-driven rise in Bacillota and boosted Verrucomicrobiota, the phylum housing Akkermansia muciniphila, a mucin-degrading bacterium celebrated for its associations with gut barrier integrity and metabolic health, and consistently depleted in patients with fatty liver disease and obesity.

Additional taxa shifts reinforced the picture. The high-fat diet enriched bile acid-resistant Lactobacillus and Limosilactobacillus species, a pattern previously linked to altered intestinal bile acid composition in fatty liver models, while the milk lipid diet selectively increased Akkermansia along with Romboutsia and members of the Christensenellaceae family, taxa reported to improve lipid metabolism partly through enhanced short-chain fatty acid production. Prior studies have shown that A. muciniphila supplementation attenuates hepatic steatosis and inflammation, modulates bile acid metabolism through the intestinal FXR-FGF15 axis, and enhances mitochondrial fatty acid oxidation via L-aspartate signaling along the gut-liver axis. The authors are appropriately measured about causality, emphasizing that their microbial findings show association rather than proof and that future work measuring microbial metabolites such as short-chain fatty acids and bile acids will be needed to close the loop.

Taken together, the study sketches a coordinated mechanism in which a single dietary component acts simultaneously on intracellular lipogenic signaling and on the ecology of the gut, offering a template for how food-derived bioactives might be engineered into functional ingredients for metabolic disease. The caveats are real: the work was conducted in mice, the intervention used a concentrated extract at a dose that would be difficult to translate directly to human diets, and the mechanistic links remain partly inferential. But with fatty liver disease affecting hundreds of millions of people and no approved pharmacological therapy for its early stages, the idea that the humble membrane lipids enveloping fat droplets in milk could simultaneously quiet a liver’s fat-building program and cultivate a healthier gut community is precisely the kind of convergent finding that could shape the next generation of nutritional interventions.

Subject of Research: Effects of dietary milk polar lipids on hepatic lipid accumulation, Wnt-PPARγ signaling, and gut microbiota in a mouse model of non-alcoholic fatty liver disease

Article Title: Dietary milk polar lipids ameliorate hepatic lipid accumulation through coordinated regulation of Wnt-PPARγ signaling and remodeling of the gut microbiota

Article References: Kim, H., Park, D., Kwon, Y.-J., & Imm, J.-Y. (2026). Dietary milk polar lipids ameliorate hepatic lipid accumulation through coordinated regulation of Wnt-PPARγ signaling and remodeling of the gut microbiota. Food Science of Animal Resources, 46(1), Article 83. https://doi.org/10.1007/s44463-026-00100-w

Image Credits: AI Generated

DOI: 10.1007/s44463-026-00100-w

Keywords: milk polar lipids, non-alcoholic fatty liver disease, Wnt/beta-catenin signaling, PPARgamma, gut microbiota, Akkermansia muciniphila, sphingomyelin, hepatic steatosis, short-chain fatty acids, gut-liver axis, high-fat high-sucrose diet, milk fat globule membrane

MASLD, previously known as non-alcoholic fatty liver disease, has become the most prevalent chronic liver condition globally, with an estimated worldwide prevalence of approximately 38 percent based on recent systematic reviews. It ranges from simple fat accumulation to inflammation and fibrosis and can progress to cirrhosis and hepatocellular carcinoma. There are few approved pharmacological treatments, and understanding the underlying molecular drivers is a priority for researchers. Mitochondrial dysfunction has long been recognized as a central feature of MASLD. Mitochondria are the energy factories of the hepatocyte, and when they fail, fatty acids accumulate inside the cell and inflammatory damage follows. Mitophagy — the selective autophagic degradation of damaged mitochondria — is the cell’s quality control system for keeping its mitochondrial network healthy. Earlier work from other groups has shown that restoring mitophagy, for instance with quercetin or cyanidin-3-O-glucoside, can improve fatty liver disease in animal models, and that impaired mitophagy is a mechanistic biomarker in patients with the disease. But the regulatory circuits that shut mitophagy down during MASLD development have remained incompletely mapped.

The new study, led by Mei Long of the Department of Rheumatology and Immunology at the First Affiliated Hospital of Hengyang Medical School, University of South China, together with Kewei Tan of the No. 922 Hospital of the People’s Liberation Army Joint Logistics Support Force and Yujie Dong of the Department of Ultrasound Medicine at the same institution, set out to fill that gap. The researchers first profiled ZNF143, a zinc finger transcription factor that binds specific GC-rich DNA motifs and acts both as an activator and repressor of transcription. ZNF143 is best studied in cancer biology, where it promotes glioma growth through KPNA2-mediated Hippo signalling and supports breast cancer cell survival through the NQO1–p53–Beclin1 axis under metabolic stress. Prior work by the same team had already implicated ZNF143 in fatty liver disease, showing that it inhibits hepatocyte mitophagy by upregulating the long non-coding RNA NEAT1 and activating the ROCK2 pathway. The current study extends that work by identifying an entirely separate, protein-level arm of the same transcription factor’s suppressive effect on mitochondrial quality control.

To test their hypothesis, the researchers used two complementary models of MASLD. The first was an in vivo model in which C57BL/6J mice were fed a high-fat diet for 16 weeks to induce hepatic steatosis and metabolic stress. The second was an in vitro model in which Huh-7 human hepatoma cells, a standard hepatic cell line, were exposed to free fatty acids to mimic lipid overload. Histological changes were assessed by hematoxylin and eosin staining, lipid accumulation was quantified by Oil Red O staining, and mitochondrial damage was assessed with JC-1 staining to monitor mitochondrial membrane potential and transmission electron microscopy to visualize mitochondrial ultrastructure. Serum and tissue markers of liver injury, including alanine aminotransferase, aspartate aminotransferase, total cholesterol and triglycerides, were measured to gauge the severity of hepatic dysfunction.

When the team examined the high-fat-diet-fed mice and the free-fatty-acid-treated Huh-7 cells, they found that ZNF143 was significantly upregulated in both settings, consistent with a role for this transcription factor in disease progression rather than simply a bystander effect. When the researchers knocked down ZNF143 using RNA interference, the consequences were striking: lipid accumulation in the liver decreased, mitochondrial damage was reduced, and liver injury markers fell. The mechanism behind this improvement was traced to a restoration of hepatocyte mitophagy, confirming that ZNF143 acts as a brake on mitochondrial quality control during MASLD.

The next step was to identify the transcriptional target through which ZNF143 exerts its effect. Using chromatin immunoprecipitation, the researchers demonstrated that ZNF143 binds directly to the promoter region of SMURF1, a HECT-type E3 ubiquitin ligase known for its role in ubiquitinating and degrading diverse substrate proteins in cancer, vascular remodeling and inflammatory signalling. Dual-luciferase reporter assays confirmed that this binding functionally activates SMURF1 transcription. In other words, ZNF143 does not merely correlate with MASLD; it actively turns up the expression of a ubiquitin ligase that then acts downstream.

SMURF1 has a complicated history in liver biology. Previous studies have shown that deleting Smurf1 attenuates liver steatosis in mice by stabilizing p53, and that Smurf1 aggravates fatty liver disease by stabilizing SREBP-1c, a master regulator of lipid synthesis, in an E3-activity-independent manner. Conversely, another study reported that SMAD-specific E3 ubiquitin protein ligase 1 can be protective in alcoholic steatohepatitis. The current study adds a new substrate to SMURF1’s growing portfolio in hepatic disease and clarifies how this E3 ligase suppresses mitochondrial quality control. Using co-immunoprecipitation, the team showed that SMURF1 physically interacts with TRPV1, the transient receptor potential vanilloid type 1 ion channel, and that SMURF1 ubiquitinates TRPV1, leading to its proteasomal degradation. TRPV1, the receptor activated by capsaicin, the pungent compound in chili peppers, has long been linked to metabolic health. Activation of TRPV1 by dietary capsaicin improves visceral fat remodelling through calcium influx, and TRPV1 activation prevents fatty liver disease in mice through upregulation of the mitochondrial uncoupling protein UCP2. By degrading TRPV1, SMURF1 removes a protective channel that supports mitochondrial and metabolic homeostasis in the hepatocyte.

The researchers then performed epistasis experiments to confirm the hierarchy of the pathway. When they knocked down TRPV1 in free-fatty-acid-treated Huh-7 cells that had already had ZNF143 depleted, the beneficial effect of ZNF143 knockdown on mitophagy was reversed. Similarly, overexpressing SMURF1 in ZNF143-depleted cells abolished the improvement in mitochondrial clearance. These results established that ZNF143 acts upstream of SMURF1 and TRPV1 in the same linear pathway: ZNF143 turns on SMURF1 transcription, SMURF1 ubiquitinates TRPV1 and targets it for degradation, and loss of TRPV1 suppresses mitophagy, leading to mitochondrial dysfunction and fat accumulation.

The significance of the finding is twofold. First, it adds to the emerging view that MASLD is fundamentally a disorder of impaired mitochondrial turnover, not simply one of excessive lipid synthesis. Multiple groups have shown that PINK1/Parkin-mediated mitophagy relieves fatty liver disease and that reversing Parkin-related mitophagy attenuates the condition. The current work identifies ZNF143 as a transcriptional switch that turns this quality control system off, providing a mechanistic explanation for why mitophagy declines during disease progression. Second, the study places TRPV1 — a channel best known from pain biology and dietary capsaicin research — at the centre of hepatic mitochondrial homeostasis. Recent work has implicated TRPV1 in mitophagy regulation in other contexts as well, including a 2025 report showing that TRPV1 inhibits both ferroptosis and mitophagy in heart failure through SFXN2, and a 2020 study showing that blocking TRPV1 promotes terminal mitophagy in multiple myeloma. The context-dependent role of TRPV1 in mitophagy across different tissues remains an open question, but the current study firmly establishes it as a downstream effector of ZNF143 in hepatocytes.

Therapeutically, the pathway offers several potential points of intervention. Small-molecule inhibitors of ZNF143 activity have already been developed for cancer applications, including YPC-21661 and YPC-22026, which were shown to inhibit ZNF143 activity both in vitro and in vivo. Inhibitors of SMURF1 have been designed for pulmonary arterial hypertension, suggesting that pharmacological tools against this E3 ligase could be repurposed for metabolic liver disease. Alternatively, TRPV1 agonists such as capsaicin or its analogues could theoretically compensate for the loss of TRPV1 protein caused by SMURF1-mediated degradation, consistent with epidemiological and experimental data suggesting that capsaicin may promote vascular and metabolic health. The authors note that the study’s findings, generated in mice and in a human hepatoma cell line, will need to be validated in human tissue samples and in additional model systems before any clinical translation.

The research was performed in accordance with guidelines approved by the Medical Ethics Committee of the First Affiliated Hospital of University of South China, and all authors declare no conflict of interest. The datasets generated and analysed during the study are available within the published article. As global rates of MASLD continue to climb in parallel with obesity and type 2 diabetes, identifying transcription factors such as ZNF143 that govern mitochondrial quality control provides a mechanistic framework for understanding disease progression and offers a roadmap for developing targeted therapies that restore the hepatocyte’s ability to clear its damaged mitochondria before steatosis spirals into inflammation, fibrosis and cancer.

At the core of the discussion is MASLD, a prevalent liver condition marked by abnormal fat accumulation in the liver coupled with metabolic dysfunction. It has gained notoriety as a significant public health concern globally. The disease spectrum encompasses a range of conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma. As lifestyle-related diseases proliferate, understanding MASLD’s implications on systemic health, particularly bone density, becomes increasingly relevant.

Bone health is an intricate interplay influenced by genetics, lifestyle, nutrition, and various health conditions. Osteoporosis emerges as one of the most common metabolic disorders, significantly impacting bone strength and increasing fragility fractures. The juxtaposition of these two conditions presents a multifaceted challenge, propelling researchers to investigate the potential interplay and disentangle the factors linking MASLD and osteoporosis.

The review meticulously compiles various studies, revealing disparate findings regarding the relationship between liver disease and bone health. Some evidence indicates that the inflammatory and metabolic changes associated with MASLD could negatively influence bone density and strength. Mechanistically, liver dysfunction can alter the metabolism of vitamin D and calcium, essential nutrients for bone health, potentially predisposing individuals to osteoporosis.

However, contrasting studies suggest that this relationship may not be straightforward. Certain individuals with MASLD exhibit preserved bone density, raising critical questions about predisposing factors and the biological mechanisms at play. Such variability could stem from genetic predispositions, lifestyle factors, dietary habits, and even variations in the disease’s progression. These inconsistencies underscore the nuanced and multifactorial nature of the relationship between these two seemingly disparate conditions.

Additionally, the review highlights potential mediators that might modify the relationship between MASLD and osteoporosis. Insulin resistance, often accompanying metabolic disorders, appears to be a crucial player in this ongoing saga. Insulin’s role in bone remodeling is increasingly recognized, raising the possibility that hyperinsulinemia characteristic of metabolic syndrome may directly affect bone health and contribute to decreased bone mineral density in affected individuals.

Furthermore, the review sheds light on the importance of sex and age as pivotal factors influencing this association. Women, particularly postmenopausal individuals, often experience accelerated bone loss due to estrogen deficiency. In conjunction with MASLD, this demographic may represent a particularly vulnerable cohort for osteoporosis, juxtaposing metabolic health and skeletal integrity.

Moreover, the interplay between lifestyle choices and MASLD cannot be overstated. Nutritional patterns, physical activity levels, and body composition significantly impact both conditions. The review emphasizes the need for comprehensive lifestyle interventions to mitigate both MASLD and osteoporosis risks concurrently, advocating for integrated approaches in clinical practice that prioritize metabolic health alongside skeletal well-being.

As researchers explore these intricate relationships, novel biomarkers and therapeutic targets are being identified, presenting exciting avenues for future research. Understanding the biological underpinnings of the MASLD-osteoporosis connection may yield innovative treatment strategies, potentially transforming clinical management for patients affected by both conditions.

This review, therefore, serves as a clarion call for collaborative research efforts aimed at elucidating this complex relationship. Multi-disciplinary approaches encompassing hepatology, endocrinology, and nutrition will be fundamental in deciphering the various layers of interactions and establishing robust clinical guidelines that address the intersectionality of MASLD and osteoporosis.

In the realm of public health, the implications of these findings extend far beyond individual patient care. The alarming rise in metabolic disorders necessitates a holistic approach to health intervention programs that emphasize prevention and risk mitigation. Policymakers must acknowledge the interconnected nature of these conditions, advocating for comprehensive health strategies that encompass lifestyle education, access to care, and multidisciplinary treatment modalities.

In summary, the contested association between MASLD and osteoporosis opens a Pandora’s box of possibilities and challenges. As clinicians strive to manage patients in an increasingly complex landscape of metabolic health, the insights garnered from this narrative review underscore the urgency to refine our understanding, elevate research priorities, and ultimately improve patient outcomes.

In conclusion, the intersection of MASLD and osteoporosis elucidates a compelling narrative fraught with contradictions yet rich in potential for scientific inquiry. As more nuanced understandings of these interconnected health concerns unfold, we stand on the precipice of transformative advancements that could dramatically reshape our approach to patient care in the ever-evolving landscape of metabolic health.

Subject of Research: The association between Metabolically Associated Steatotic Liver Disease (MASLD) and osteoporosis.

Article Title: The contested association between MASLD and osteoporosis: a narrative review of heterogeneous evidence and modifying factors.

Article References:

Xiao, YJ., Zhang, YL., Mao, XZ. et al. The contested association between MASLD and osteoporosis: a narrative review of heterogeneous evidence and modifying factors.
Arch Osteoporos 21, 22 (2026). https://doi.org/10.1007/s11657-025-01639-9

Image Credits: AI Generated

DOI: 10.1007/s11657-025-01639-9

Keywords: MASLD, osteoporosis, liver disease, metabolic health, bone density, insulin resistance, lifestyle interventions, public health.

Circadian rhythms regulate numerous biological processes, influencing everything from sleep patterns to metabolism. Deviation from these natural cycles, often triggered by lifestyle factors such as shift work, irregular sleep schedules, or frequent travel across time zones, can lead to serious health repercussions. Research has long highlighted the implications of circadian disruption on metabolic health, but clarity on the molecular mechanisms driving such conditions was lacking until now. This research lays the groundwork by meticulously detailing the pathways involved in the relationship between these seemingly disconnected areas.

The team employed a mouse model to study the effects of circadian disruptions on liver pathology, particularly focusing on the development of non-alcoholic fatty liver disease. This condition is characterized by excessive fat accumulation in liver cells, occurring in individuals who consume little to no alcohol. As the prevalence of NAFLD continues to rise globally, understanding its etiology has become urgent. The team’s findings underscore the correlation between altered circadian rhythms and increased susceptibility to this disease.

Through their experimental design, the researchers manipulated light-dark cycles to induce circadian disruption in test subjects. This strategic approach allowed them to observe significant physiological changes within the liver, including increased fat accumulation, liver inflammation, and the activation of specific death pathways within cells. These phenomena indicate that the liver is particularly sensitive to circadian misalignment, demonstrating how crucial timing is to its health and function.

Central to the findings is the activation of the RIPK1-RIPK3-MLKL cell death signaling axis. This signaling pathway has been implicated in various forms of cell death, including necroptosis—a regulated form of necrosis that can lead to significant tissue damage and inflammation. The study identified that circadian disruption activates this axis, contributing to hepatic inflammation and worsening the fatty liver pathology in the affected mice. This connection emphasizes the intricate relationship between our biological clocks and cellular health mechanisms.

Furthermore, the research delves into the specifics of how these signaling pathways engage following circadian disruption. Not only do they establish that RIPK1, RIPK3, and MLKL expression levels are affected, but they also illustrate the consequences of this altered expression on liver functional integrity. Key metabolic processes begin to fail, ultimately resulting in an accumulation of lipids, indicative of fatty liver disease. This detailed investigation provides a molecular basis for the observable physiological changes in NAFLD, paving the way for further exploration into treatment avenues.

The implications of these findings extend beyond the laboratory. For individuals facing circadian disruptions due to modern lifestyle demands, such as irregular work hours or excessive screen time before bed, this research serves as a timely warning about the potential health costs. Furthermore, it highlights the necessity for lifestyle adjustments and potential interventions that could mitigate circadian misalignment’s harmful effects on liver health—and by extension, overall metabolic health.

The study also raises questions about the potential for pharmacological intervention targeting the RIPK1-RIPK3-MLKL axis. If circadian disruptions contribute to the worsening of diseases through this specific pathway, therapeutics that modulate this signaling cascade could represent a novel approach to treat or prevent NAFLD. The researchers advocate for further exploration into compounds that may be able to address the effects of circadian misalignment on liver health and explore options that can synchronize biological rhythms.

Moreover, the research underscores the significance of public health messaging regarding the importance of maintaining regular sleep patterns and overall lifestyle harmony. As we increasingly recognize the complex relationship between our environments and our biological systems, interventions that promote better circadian alignment could have far-reaching implications for liver health and metabolic disorders at large.

In reviewing the study’s methodology, it is essential to acknowledge the rigor involved in conducting experiments using animal models. By meticulously syncing the disruptions with carefully monitored physiological responses, the research team was able to capture the nuances of how circadian rhythm interference can progressively aggravate liver disease pathology. This level of detail is critical for understanding the translational potential of these findings to human health concerns surrounding NAFLD.

In conclusion, this pioneering research underscores the vital interplay between our body clocks and the mechanisms underpinning liver disease. As circadian disruption becomes more prevalent in modern society, studies like these illuminate the urgency of identifying effective preventive measures for metabolic diseases like non-alcoholic fatty liver disease. By fostering a greater understanding of these interactions, researchers are positioning the medical community to devise informed strategies to promote better health outcomes for individuals living with the repercussions of altered circadian rhythms.

With future studies aimed at addressing the therapeutic potential of targeting the RIPK1-RIPK3-MLKL axis, we have reason to be optimistic about innovative solutions to combat NAFLD and enhance liver health—particularly in an era where maintaining a harmonious relationship with our biological clocks is increasingly challenging.

The unfolding narrative within this realm of biomedical research beautifully illustrates how fundamental aspects of our biology are intertwined with environmental influences. The findings not only contribute to the existing body of knowledge but also help pave the way for holistic health interventions that embrace both medical and lifestyle approaches to optimize liver health and prevent disease progression.

As this research captures the attention of the scientific community and the public alike, we must remain vigilant in addressing and promoting awareness of circadian health, ultimately leading to better prevention and management of non-alcoholic fatty liver disease.

Subject of Research: Circadian Disruption and Non-Alcoholic Fatty Liver Disease

Article Title: Circadian disruption aggravates non-alcoholic fatty liver disease by activating RIPK1-RIPK3-MLKL axis in mice.

Article References:

Li, X., Wang, L., Cheng, X. et al. Circadian disruption aggravates non-alcoholic fatty liver disease by activating RIPK1-RIPK3-MLKL axis in mice.
Sci Rep (2025). https://doi.org/10.1038/s41598-025-32711-6

Image Credits: AI Generated

DOI:

Keywords: Circadian Rhythm, Non-Alcoholic Fatty Liver Disease, RIPK1, RIPK3, MLKL, Cell Signaling, Metabolic Disorder.

NAFLD, characterized by the abnormal accumulation of fat in liver cells not caused by alcohol consumption, has surged in prevalence alongside global increases in obesity and metabolic syndrome. Despite its widespread impact, the molecular drivers that govern the transition from benign steatosis to inflammation, fibrosis, and ultimately cirrhosis remain poorly understood. The current research addresses this critical gap by focusing on the role of the ubiquitin-proteasome system, a key regulatory pathway responsible for protein turnover and cellular homeostasis.

The E3 ubiquitin ligase TRIM7 has emerged as a multifaceted enzyme involved in various cellular functions, including signaling pathway modulation and immune responses. This study demonstrates that TRIM7 directly interacts with DUSP10, a known negative regulator of the mitogen-activated protein kinase (MAPK) pathway, tagging it for proteasomal degradation. By targeting DUSP10, TRIM7 effectively removes a crucial brake on MAPK signaling, resulting in enhanced inflammatory and fibrotic responses within the liver microenvironment.

The experimental design employed male murine models genetically engineered to either overexpress or lack TRIM7, paired with detailed histological and biochemical assessments. Elevated TRIM7 levels correlated with aggravated hepatic steatosis, increased inflammation, and fibrosis markers, indicating its causal role in disease progression. Conversely, TRIM7 deficiency conferred a protective phenotype, with significantly reduced liver damage under high-fat diet conditions. These findings provide robust in vivo evidence of TRIM7 as a key modulator in NAFLD pathogenesis.

At the molecular level, the degradation of DUSP10 by TRIM7 removes its inhibitory effects on MAPK pathways, notably p38 and JNK, which are well-documented mediators of pro-inflammatory cytokine production and fibrogenesis. The study elucidates how sustained MAPK activation fosters the activation of hepatic stellate cells and macrophages—two cell types instrumental in promoting liver inflammation and fibrotic tissue remodeling. This mechanistic insight establishes a direct link between TRIM7 enzymatic activity and cellular processes driving NAFLD worsening.

Targeting TRIM7 or stabilizing DUSP10 represents a novel therapeutic strategy that could halt or reverse NAFLD progression. Pharmacological inhibition of TRIM7’s ligase function may restore DUSP10 levels, thereby reining in MAPK-driven inflammatory cascades. The research team highlights the potential of small molecules or biologics designed to impede TRIM7-DUSP10 interaction as promising candidates for future drug development. Such innovative treatment approaches, if successful, could dramatically reduce the burden of liver disease complications including cirrhosis and hepatocellular carcinoma.

Beyond its implications for NAFLD, the study underscores the broader significance of the ubiquitin-proteasome system in chronic metabolic disorders. Dysregulated protein degradation contributes to cellular dysfunction across a spectrum of diseases, and delineating the specific molecular players offers unprecedented opportunities for precision medicine. This research exemplifies how dissecting ubiquitin ligases like TRIM7 can illuminate pathological pathways and inform highly specific, mechanism-based therapies.

Sex-specific differences emerged as a notable aspect of the investigation, with male mice demonstrating more pronounced TRIM7-mediated effects. This observation aligns with clinical data indicating higher NAFLD prevalence and severity among men, suggesting intrinsic molecular determinants underlying gender disparities in liver disease. Understanding how TRIM7 expression and activity are regulated by sex hormones may reveal additional layers of complexity in disease susceptibility and treatment response.

The research incorporated cutting-edge techniques including CRISPR-Cas9 gene editing, proteomics, and in vivo metabolic flux analysis, providing a comprehensive, multi-dimensional understanding of TRIM7’s role. Such integrative methodologies highlight the importance of combining genetic, biochemical, and cellular assays to unravel complex disease mechanisms. The precision and rigor of these experimental approaches enhance the translational relevance of the study’s conclusions.

Importantly, this discovery positions TRIM7 as a potential biomarker for NAFLD progression. Quantifying TRIM7 expression or activity in liver tissue or circulating exosomes may enable early detection of disease advancement and stratification of patients for personalized treatment regimens. Biomarkers linked to causative molecular events hold particular value in clinical settings, where early intervention dramatically improves outcomes.

The study’s findings contribute to a growing body of literature emphasizing the role of intracellular signaling regulation in metabolic diseases. The interplay between ubiquitination processes and kinase signaling pathways defines a critical node in cellular stress response and inflammation. By pinpointing TRIM7 as a central orchestrator, the research enriches our understanding of how these systems go awry in chronic liver conditions.

Future research directions include exploring the upstream regulators of TRIM7 expression and activity, as well as investigating its role in human NAFLD samples and other preclinical models. Elucidating whether TRIM7 has analogous functions in female subjects or in other metabolic organs will be crucial for comprehensive disease modeling. Moreover, clinical studies are needed to evaluate the safety and efficacy of potential TRIM7 inhibitors in patients with fatty liver disease.

This seminal work not only advances scientific knowledge but also holds tangible promise for addressing a global health challenge. NAFLD is projected to become the leading indication for liver transplantation worldwide, underscoring the urgent need for new therapeutic targets. The identification of TRIM7 as a molecular driver offers a beacon of hope for innovative treatments that may transform the clinical management of this burdensome condition.

In summary, the elucidation of TRIM7’s enzymatic role in promoting non-alcoholic fatty liver disease by targeting DUSP10 adds a crucial piece to the complex puzzle of liver pathology. The mechanistic insights derived from this study pave the way for novel therapeutic strategies aimed at modulating protein degradation pathways to ameliorate disease progression. As research in this domain advances, the potential to translate these findings into clinical practice grows ever more tangible.

The nexus between ubiquitination and kinase signaling revealed by the TRIM7-DUSP10 axis marks a paradigm shift in understanding metabolic liver diseases. This study exemplifies how fundamental cellular biology can drive breakthroughs in disease intervention, illustrating the enduring power of molecular medicine to unlock new horizons for patient care.

Subject of Research: The role of the E3 ubiquitin ligase TRIM7 in the progression of non-alcoholic fatty liver disease via degradation of DUSP10 in male mice.

Article Title: The E3 ligase tripartite motif 7 drives the progression of non-alcoholic fatty liver disease by targeting DUSP10 degradation in male mice.

Article References:
Yan, FJ., Ding, H., Zhang, N. et al. The E3 ligase tripartite motif 7 drives the progression of non-alcoholic fatty liver disease by targeting DUSP10 degradation in male mice. Nat Commun 16, 10437 (2025). https://doi.org/10.1038/s41467-025-65415-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65415-6

NAFLD is characterized by the accumulation of fat in liver cells, independent of alcohol consumption. With increasing rates of obesity and metabolic syndrome worldwide, NAFLD has become one of the most common liver diseases. Its association with various metabolic risk factors, including insulin resistance, dyslipidemia, and hypertension, underscores the importance of understanding the underlying mechanisms that drive this condition. The implications of this study extend beyond mere academic curiosity; they touch on pressing public health issues that require immediate attention.

The researchers aimed to elucidate the relationship between serum uric acid—a product of purine metabolism—and creatinine, a byproduct of muscle metabolism, particularly in the context of metabolic disturbances associated with NAFLD. Their hypothesis was built upon existing literature that has suggested an intriguing connection between elevated levels of uric acid and various metabolic disorders, including obesity and type 2 diabetes, both of which are closely associated with NAFLD. By investigating this relationship, the researchers strived to identify potential biomarkers that could aid in the early detection and management of this liver disease.

Utilizing a sample of patients diagnosed with NAFLD, the researchers conducted a comprehensive analysis to evaluate the serum uric acid to creatinine ratio. The focus on this ratio is particularly compelling, as it offers a nuanced view of renal function alongside metabolic health. Elevated uric acid has long been regarded as an independent risk factor for metabolic syndrome and may complicate the clinical picture of NAFLD due to its role in inflammation and oxidative stress, both of which are key pathological features of the disease.

Findings from the study indicated a significant association between higher serum uric acid to creatinine ratios and adverse metabolic profiles in individuals suffering from NAFLD. As such, the data suggest that this biomarker could serve as a valuable tool in identifying patients at higher risk for severe liver disease and associated metabolic complications. This correlation also opens new avenues for therapeutic interventions that target uric acid levels, potentially offering new hope for better treatment outcomes.

Moreover, the distinction between serum uric acid and creatinine levels emphasizes the importance of integrating multiple biomarkers into the assessment of NAFLD. Clinicians often rely heavily on traditional liver enzyme tests; however, the findings from this study encourage a more holistic approach that considers a broader panel of metabolic indicators. By understanding the interconnectedness of these biomarkers, healthcare providers can enhance their diagnostic accuracy and make more informed decisions regarding treatment strategies.

The implications of such research extend beyond the individual patient, potentially influencing public health policies and healthcare systems as a whole. With NAFLD projected to rise significantly, awareness of its metabolic implications can drive healthcare initiatives aimed at preventing this condition. Education about dietary choices, lifestyle changes, and clinical assessments can help curb the rising tide of NAFLD, aligning with global initiatives to reduce the burden of liver disease.

Ultimately, increased collaboration between researchers, healthcare providers, and policymakers is essential to address the growing challenges posed by NAFLD and its associated metabolic risks. By effectively translating such research findings into clinical practice, we can improve early detection rates and develop individualized treatment plans that cater to the unique metabolic profiles of patients. This integrative approach may not only enhance patient outcomes but also contribute to a more sustainable healthcare system focused on proactive management.

As research continues to unveil more about the pathophysiology of NAFLD and its relationship with metabolic disorders, the development of innovative diagnostic tools could soon become a reality. Emerging technologies in genomics, proteomics, and metabolomics promise to provide deeper insights into individual patient profiles. Consequently, the potential for personalized medicine in treating NAFLD could position clinicians to offer targeted therapies that address the root causes of the disease, rather than merely its symptoms.

In summary, the association between serum uric acid to creatinine ratio and metabolic profile in individuals with NAFLD presented in the study by El-Sehrawy and colleagues is a crucial step toward the refinement of diagnostic practices and treatment modalities. When clinical practice aligns closely with current research, patients are likely to benefit from enhanced evaluation strategies that consider a comprehensive view of health. As metabolic disorders such as NAFLD continue to increase in prevalence, prioritizing research and its application will be pivotal in shaping the future of liver health management.

In conclusion, the findings of this research spark a crucial dialogue about the need for innovative approaches and rigorous scientific inquiry into NAFLD and its complex interactions with metabolic parameters. The implications of these discoveries could resonate throughout the healthcare community, impacting how we understand, diagnose, and treat this increasingly prevalent condition. Moving forward, the integration of new evidence with clinical applications will pave the way for better healthcare strategies and improved outcomes for thousands of individuals affected by NAFLD.

Subject of Research: The association between serum uric acid to creatinine ratio and metabolic profile in individuals with non-alcoholic fatty liver disease (NAFLD).

Article Title: Association between serum uric acid to creatinine ratio with metabolic profile in subjects with non-alcoholic fatty liver disease (NAFLD).

Article References:

El-Sehrawy, A.A.M.A., Alshkarchy, S.S., Kareem, A.K. et al. Association between serum uric acid to creatinine ratio with metabolic profile in subjects with non-alcoholic fatty liver disease (NAFLD).
BMC Endocr Disord 25, 260 (2025). https://doi.org/10.1186/s12902-025-02074-0

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12902-025-02074-0

Keywords: NAFLD, serum uric acid, creatinine, metabolic profile, liver disease, biomarkers, public health.

The contemporary prevalence of metabolic diseases in India cannot be overstated, especially concerning the alarming rates of obesity and diabetes. As urbanization and lifestyle changes continue to influence dietary habits across the nation, the implications of these trends manifest prominently in the liver’s health. MASLD is increasingly recognized in both clinical practice and research, making it vital for healthcare professionals to understand its implications within the Indian context. Notably, MASLD is not merely a consequence of excessive alcohol consumption but is often attributed to the accumulation of fat in the liver in non-alcoholic individuals, highlighting the importance of focusing on non-alcoholic fatty liver diseases (NAFLD).

Bose and colleagues advocate for the need to tailor research to encompass the unique genetic, environmental, and lifestyle factors that contribute to the prevalence of MASLD in Indian populations. The presence of varying metabolic phenotypes within the country necessitates an interdisciplinary approach to unravel the disease’s complexities. The MAP Study provides a foundational framework for acknowledging these disparities, offering a lens through which targeted interventions and treatments can be developed.

The expertise of these authors lends credibility to their assertions. They shed light on the lore surrounding metabolic dysfunctions in underestimated demographics, particularly among younger populations that are increasingly presenting with fatty liver diseases. In India, this trend signifies a shift in health paradigms, emphasizing the urgent need for early detection and intervention strategies tailored to these emerging profiles. Given this shift, educational campaigns targeting dietary modifications and lifestyle adjustments hold promise as preventative measures against MASLD.

Moreover, the researchers highlight the role of socioeconomic factors in influencing susceptibility to MASLD. Lower income levels and limited access to healthcare services play a significant role in the prevalence of metabolic diseases in various strata of Indian society. Consequently, enhancing public health policies to address these disparities will prove essential in curbing the rising tide of MASLD cases. Additionally, the intersection of culture, community practices, and consumption patterns deserves further exploration in future studies, as these factors are integral to understanding disease spread and management.

It is also imperative to include an exploration of the molecular mechanisms underlying MASLD. The biochemical interactions within the liver cells can be complex and multifactorial, involving genetic predispositions, insulin resistance, and oxidative stress. Furthermore, the pathological progression from simple steatosis to more severe forms, such as steatohepatitis or cirrhosis, warrants investigation to establish clear early biomarkers for intervention. Understanding these processes could equip healthcare professionals with the necessary tools to anticipate and manage MASLD effectively.

The implications of this research extend beyond India, as global health trends shift towards non-communicable diseases. The findings elucidated in the MAP study and the subsequent correspondence by Bose, Sridharan, and Gupta serve as a crucial reminder that metabolic diseases can transcend borders. The insights gleaned from the Indian population may also resonate with other regions facing similar epidemiological transitions, emphasizing a need for a global approach to combatting MASLD.

Furthermore, the interplay between obesity, diabetes, and MASLD opens new avenues for future research. Investigating the links between these conditions could reveal novel therapeutic targets and strategies for effective disease management. The letter encourages researchers to engage with multi-faceted approaches that combine pharmacological interventions with lifestyle modifications in addressing MASLD.

The role of technology in managing MASLD also cannot be overlooked. Digital health solutions can facilitate patient adherence to therapeutic regimens and offer a platform for ongoing education on best practices for liver health. Mobile health applications designed with user-friendly interfaces can foster engagement and promote lifestyle changes necessary for preventing MASLD. As digital interventions gain traction, they may provide a cost-effective solution for healthcare systems grappling with an increase in metabolic diseases.

Moreover, as the field of personalized medicine evolves, acknowledging individual variability in responses to treatments will be crucial. Genetic screening for susceptibilities to MASLD can guide healthcare providers in crafting tailored treatment plans to improve outcomes. Personalization in managing health not only optimizes therapeutic efficacy but also empowers patients to take charge of their health journeys.

In summary, the letter to the editor authored by Bose and colleagues brings to the forefront significant issues surrounding MASLD in the context of Indian demographics. Their call to action is clear: prioritize research that embraces genetic, environmental, and sociocultural factors influencing this disease. As the country grapples with soaring rates of metabolic disorders, public and private sectors must collaborate to implement strategies that mitigate risks associated with MASLD.

Ultimately, the researchers emphasize the invaluable role of continued discourse in clinical and academic circles regarding MASLD. They strongly advocate for a concerted effort to challenge the status quo, broaden understanding, and develop actionable solutions to combat this escalating health burden. This letter serves as both a reflective piece and a beacon for future research directions, forming a critical part of the conversation surrounding metabolic diseases in India and potentially elsewhere.

The need for urgent action is underscored in every paragraph, highlighting the risks associated with inaction. As understanding of MASLD grows, so too must our responses to it. Enhanced healthcare practices, reinforced by cutting-edge research and collective community engagement, will be paramount in addressing this troubling trend and safeguarding future generations against the consequences of metabolic dysfunction.

Subject of Research: Metabolic Dysfunction-Associated Steatotic Liver Disease in Indian Populations

Article Title: Letter to the Editor Regarding ‘Profile of Metabolic Dysfunction-Associated Steatotic Liver Disease: Mapping Across Different Indian Populations (MAP Study)’

Article References:

Bose, R., Sridharan, K. & Gupta, R. Letter to the Editor Regarding ‘Profile of Metabolic Dysfunction-Associated Steatotic Liver Disease: Mapping Across Different Indian Populations (MAP Study)’. Diabetes Ther (2025). https://doi.org/10.1007/s13300-025-01808-6

Image Credits: AI Generated

DOI: 10.1007/s13300-025-01808-6

Keywords: Metabolic Dysfunction, Steatotic Liver Disease, Indian Populations, Research, Public Health, Diabetes, Obesity.

Acanthopanax trifoliatus, commonly known as the thorny ginseng, is a plant renowned for its diverse medicinal properties. It has been used for centuries in traditional medicine for its supposed health benefits, including anti-inflammatory, antioxidant, and immune-boosting effects. In the current study, researchers sought to investigate the specific hepatoprotective abilities of this plant, focusing on how its extracts could mitigate liver damage, a common health issue stemming from various causes such as alcohol consumption, viral infections, and metabolic disorders.

The backdrop of this research is critical, given the increasing prevalence of liver diseases worldwide. Conditions like non-alcoholic fatty liver disease (NAFLD), hepatitis, and cirrhosis continue to rise, prompting the need for effective therapeutic interventions. The authors recognize that traditional pharmacological therapies often come with significant side effects and limitations, thereby highlighting the potential of phytotherapy as a viable alternative. This study positioned Acanthopanax trifoliatus as a promising candidate for further exploration in the field of hepatoprotection.

In their methodology, the researchers utilized a HepG2 cell line, which is derived from human liver carcinoma and is commonly employed as a model for studying liver function and pathology. This cell line exhibits many characteristics of normal hepatocytes, making it an ideal candidate for assessing the therapeutic effects of various compounds. The study meticulously described the isolation and standardization of the leaf extract, ensuring that the active components were accurately identified and quantified.

The results yielded significant insights into the hepatoprotective properties of the Acanthopanax trifoliatus extract. Researchers observed that treatment with the standardized extract resulted in a marked reduction in hepatocyte apoptosis and necrosis, key indicators of liver damage. Additionally, the extract exhibited a capacity to modulate oxidative stress levels, a crucial factor in the progression of liver diseases. The authors noted that the extract appeared to enhance the cellular antioxidant defense mechanisms, potentially neutralizing the harmful effects of reactive oxygen species (ROS) that often contribute to tissue damage.

These findings pave the way for further investigation into the molecular mechanisms underlying the protective effects of Acanthopanax trifoliatus. The study suggests that the active phytochemicals within the extract may influence a range of cellular pathways associated with inflammation, apoptosis, and redox homeostasis. Understanding these mechanisms is vital, as it could lead to the development of new therapeutic agents that leverage the natural properties of this plant.

In addition to its direct hepatoprotective effects, the study also examined the potential of various formulations of the leaf extract. The researchers hypothesized that different methods of extraction could yield diverse biological activities and efficacy. By exploring these formulations, the authors aimed to identify the most effective means of harnessing the plant’s benefits, thereby contributing to the field of pharmaceutical development.

While the results are promising, the authors emphasize the necessity for further research. In vitro studies, such as those conducted using HepG2 cells, provide essential preliminary data, but their findings must eventually be validated through in vivo experiments. Animal models and human clinical trials will be crucial in confirming the efficacy and safety of Acanthopanax trifoliatus as a hepatoprotective therapy. Future studies will also need to address dosage optimization and potential interactions with other medications, particularly for populations with pre-existing health conditions.

The implications of this research extend beyond the lab, offering hope to millions affected by liver diseases. As public awareness of the importance of liver health increases, the demand for natural and less invasive treatment options is likely to grow. This study positions Acanthopanax trifoliatus as an intriguing candidate for future therapeutic strategies, possibly leading to new dietary supplements or herbal medications.

The overarching message of this research is clear: the exploration of natural products is a promising avenue for discovering novel hepatoprotective agents. With the ongoing challenges posed by liver diseases, the role of traditional medicinal plants as a source of innovation in modern medicine is more relevant than ever. Studies like those conducted by Sa-ngiamsuntorn and colleagues not only enhance our understanding of plant-based therapies but also inspire future generations of researchers to continue seeking answers within the rich tapestry of nature.

As the dialogue around plant-based medicinal research unfolds, it is critical that both the scientific community and the public stay informed. Knowledge sharing and collaborative efforts will be fundamental in advancing this field, making it imperative for researchers to communicate their findings effectively. In that respect, studies like this one serve to bridge the gap between ancient wisdom and modern scientific inquiry, creating a holistic approach to healthcare that respects and utilizes the resources nature provides.

The journey of Acanthopanax trifoliatus in the realm of hepatoprotection is just beginning. With its promising results, the study invites further exploration and encourages a broader acceptance of phytotherapy as a legitimate avenue for treating liver ailments. It stands as a testament to the need for ongoing research and development within this critical area of health.

As we await future findings and advancements stemming from this research, the potential for holistic health solutions is brighter than ever. The dialogue between traditional knowledge and contemporary science continues to evolve, with Acanthopanax trifoliatus at the forefront of this vital transformation. The meticulous study by Sa-ngiamsuntorn et al. underscores the importance of rigorous scientific research in validating the therapeutic claims of natural products, offering hope for more effective treatments for liver diseases in the future.

In conclusion, the exploration of Acanthopanax trifoliatus within a HepG2 model represents a significant step forward in the quest for hepatoprotective therapies. The encouraging results prompt further investigation into the plant’s potential, opening doors to innovative treatment options that harness the power of nature. As research progresses, we can anticipate a revitalized approach to liver health management that celebrates and incorporates the benefits of phytotherapy.

Subject of Research: Hepatoprotective effects of Acanthopanax trifoliatus standardized leaf extract

Article Title: Hepatoprotective effects of Acanthopanax trifoliatus standardized leaf extract and its formulations in a HepG2 model.

Article References:

Sa-ngiamsuntorn, K., Rojsanga, P., Ruenraroengsak, P. et al. Hepatoprotective effects of Acanthopanax trifoliatus standardized leaf extract and its formulations in a HepG2 model.
BMC Complement Med Ther 25, 319 (2025). https://doi.org/10.1186/s12906-025-05025-3

Image Credits: AI Generated

DOI: 10.1186/s12906-025-05025-3

Keywords: Hepatoprotective, Acanthopanax trifoliatus, liver health, medicinal plants, phytotherapy.

The study, which is described in detail in the prestigious journal Diabetes Therapy, charts a pioneering course as it evaluates the safety, tolerability, and pharmacodynamics of LY3522348. The researchers, led by recognized scientists such as Fukuda and Thompson, explored the pharmacokinetics of this novel compound, laying the groundwork for potentially groundbreaking advancements in diabetes care. The commitment of the research team to systematic investigation reflects the critical understanding of the mechanisms underlying carbohydrate metabolism and the pivotal roles of ketohexokinases.

As non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes increase in prevalence globally, the development of new therapeutic agents like LY3522348 is crucial. Traditional management strategies have often struggled to effectively address the complex interplay of metabolic pathways contributing to diabetes. Thus, the exploration of ketohexokinase inhibition is timely and offers a fresh perspective on therapeutic options. Notably, this study’s population of healthy adults serves as a vital first step in demonstrating the drug’s safety profile prior to expanding testing to individuals with diabetes.

Pharmacodynamics assessments within this study also hint at its potential impact on weight management, a critical factor in diabetes treatment. By inhibiting ketohexokinase, LY3522348 may alter energy utilization preferentially. This shift could effectively help lower blood glucose levels and enhance overall metabolic health, paving the way for a multi-faceted approach to diabetes management that integrates both glucose control and weight reduction. Such dual benefits could be revolutionary in improving the quality of life for patients affected by diabetes.

In the study’s initial phases, researchers meticulously monitored participants for adverse effects, showcasing a rigorous drug safety evaluation process. The trials included comprehensive assessments including vital signs, biochemical analyses, and monitoring of potential side effects, thereby ensuring participant safety throughout the study. Addressing drug safety and tolerability head-on reaffirms the commitment researchers have toward both efficacy and patient well-being, further building a strong foundation for future clinical applications.

Moreover, with an increasing number of individuals diagnosed with diabetes worldwide, the urgency for innovative treatment options is magnified. LY3522348 positions itself as a beacon of hope in this context. The results from this phase one trial could potentially catalyze further studies, expanding into larger cohorts and eventually leading to long-term efficacy assessments in patients with diabetes and related metabolic disorders. This study could signal the dawn of a new chapter in diabetes management.

The researchers highlight that while the fundamental approach of targeting glucose metabolism through ketohexokinase inhibition is promising, the clinical implications will need to be understood in a broader context. Future research will be needed to decipher how this drug interacts with existing diabetes medications, as well as its long-term effects on health outcomes. Additionally, considerations regarding individual variabilities in responses to the treatment will likely influence its incorporation into regular therapeutic practices.

A hallmark aspect of the LY3522348 development is the interdisciplinary collaboration among the study’s authors and contributing researchers. Input from diverse fields of expertise not only enriches the study design but also enhances the interpretation of complex biochemical interactions involved in fructose metabolism and its implications for diabetes. This collaborative spirit encapsulates a growing recognition of the necessity for holistic approaches in biomedical research, yielding more robust findings with practical clinical applications.

Furthermore, LY3522348’s unique mechanism of action places it apart from existing diabetes therapeutics, such as SGLT2 inhibitors and GLP-1 receptor agonists, that have dominated the landscape in recent years. Each class of diabetes medication comes with its own benefits and side effects, often necessitating a careful balance of treatment options. The introduction of ketohexokinase inhibitors could foster new dynamics in diabetes pharmacotherapy, potentially leading to personalized treatment regimens tailored to the metabolic profiles of individual patients.

Equipped with this innovative research, healthcare providers may develop more effective treatment pathways that acknowledge not just glycemic control but also patient preferences and lifestyle factors. A patient-centered approach could improve compliance and, consequently, health outcomes. By leveraging new knowledge from studies like this, practitioners could more critically evaluate adjunct therapies to existing treatment plans.

Research into LY3522348 is still in its early phases, promoting enthusiasm among the scientific community. The excitement is palpable and highlights the critical need for ongoing investigation into novel metabolic pathways that may influence diabetes management. The findings serve as a reminder of the potential for new drug discoveries to arise from meticulous basic and clinical research, ultimately benefiting countless individuals affected by this chronic condition.

With diabetes impacting millions globally, the implications of LY3522348 may very well reverberate throughout the health sector, changing lives for the better. As more data emerges, it will be exciting to watch how scientists and clinicians translate these early findings into tangible benefits for patients. If successful, LY3522348 holds the potential to provide much-needed relief to those navigating the complexities of diabetes, supporting improved health outcomes and quality of life.

This research is a vital step in understanding the intricacies of diabetes treatment and reflects the dynamic nature of medical research. As more results from ongoing studies are published, the overall narrative surrounding diabetes management will continue to evolve. The scientific community eagerly anticipates the progression of LY3522348 as researchers work toward comprehensive clinical insights that can illuminate the future of diabetes therapy.

Research into innovative treatments like LY3522348 not only fuels the hope of better diabetes management but also inspires a broader inquiry into metabolic research. As the science progresses, it might unearth further therapeutic avenues, potentially leading to a paradigm shift in how diabetes and its complications are treated around the globe.

In conclusion, the first-in-human study of LY3522348 marks a seminal moment in diabetes research, combining cutting-edge techniques with a comprehensive understanding of metabolic health. This innovative approach underscores the importance of exploring novel pharmacological pathways and does not merely aim to control diabetes but to redefine how we understand and treat metabolic diseases going forward.

Subject of Research: New ketohexokinase inhibitor (LY3522348) in diabetes therapy.

Article Title: LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults.

Article References:
Fukuda, T., Thompson, B.R., Brouwers, B. et al. LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults.
Diabetes Ther 16, 1399–1415 (2025). https://doi.org/10.1007/s13300-025-01752-5

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s13300-025-01752-5

Keywords: ketohexokinase, diabetes, pharmacotherapy, glucose metabolism, metabolic disorders.